TY  - JOUR
AU  - Quintela-Fandino, Miguel
AU  - Lluch, Ana
AU  - Manso, Luis
AU  - Calvo, Isabel
AU  - Cortes, Javier
AU  - García-Saenz, José Angel
AU  - Gil-Gil, Miguel
AU  - Martinez-Jánez, Noelia
AU  - Gonzalez-Martin, Antonio
AU  - Adrover, Encarna
AU  - de Andres, Raquel
AU  - Viñas, Gemma
AU  - Llombart-Cussac, Antonio
AU  - Alba, Emilio
AU  - Guerra, Juan
AU  - Bermejo, Begoña
AU  - Zamora, Esther
AU  - Moreno-Anton, Fernando
AU  - Pernas Simon, Sonia
AU  - Carrato, Alfredo
AU  - Lopez-Alonso, Antonio
AU  - Escudero, María José
AU  - Campo, Ruth
AU  - Carrasco, Eva
AU  - Palacios, José
AU  - Mulero, Francisca
AU  - Colomer, Ramon
PY  - 2016
DO  - 10.1158/1078-0432.CCR-16-0738
UR  - http://hdl.handle.net/10668/10410
T2  - Clinical cancer research : an official journal of the American Association for Cancer Research
AB  - Purpose: We previously detected promising efficacy of neoadjuvant nintedanib (a multityrosine kinase inhibitor, TKI) in early HER2-negative breast cancer. In a preclinical study, we monitored stromal hypoxia with 18F-fluoromisonidazole-positron...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Breast Neoplasms
KW  - Female
KW  - Humans
KW  - Indoles
KW  - Middle Aged
KW  - Misonidazole
KW  - Neoadjuvant Therapy
KW  - Neoplasm Staging
KW  - Paclitaxel
KW  - Positron Emission Tomography Computed Tomography
KW  - Protein Kinase Inhibitors
KW  - Receptor, ErbB-2
KW  - Tumor Hypoxia
TI  - 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.
TY  - research article
VL  - 23
ER  -